Hydreight Technologies Inc. Announces Closing of Oversubscribed $15 Million Bought Deal LIFE Offering

Executive Summary

• Hydreight Technologies Inc. closed its previously announced bought‑deal private placement, issuing 3,705,000 units at $4.05 each for total gross proceeds of $15,005,250.
• The offering included an exercised underwriters’ option for an additional 1,235,000 units, bringing the total units issued to the full 3,705,000.
• Proceeds will be used to accelerate sales growth, expand pharmacy production lines, and fund working capital/general corporate purposes.

Key Details

• Units Issued: 3,705,000 (each unit = 1 common share + ½ warrant).
• Price per Unit: $4.05.
• Gross Proceeds: $15,005,250.
• Underwriters: Canaccord Genuity Corp. (lead underwriter/sole bookrunner) and Beacon Securities Limited.
• Underwriters’ Option: Up to 1,235,000 additional units; option exercised in full.
• Warrant Terms: Each unit includes a half‑share purchase warrant; each whole warrant allows purchase of one common share at $5.27 for 24 months from closing.
• Broker Warrants to Underwriters: 222,300 non‑transferable broker warrants exercisable at $4.05 per share for 24 months.
• Underwriter Compensation: Cash commission of $900,315 plus the broker warrants above.
• Exemptions Used: Listed Issuer Financing Exemption (NI 45‑106) in Canada; U.S. securities law exemption under Regulation S. No hold period required on the units or warrant shares.
• Use of Proceeds: Support sales growth, create/expand pharmacy production lines, working capital, and general corporate purposes as outlined in the offering document dated Jan 15 2026.

Notable Quotes

“This financing was oversubscribed within hours of announcement… With this additional capital, we are positioned to further accelerate customer growth by expanding our technology and platform offerings, increasing production capacity, accelerating new product rollouts, and strengthening the infrastructure required to support growing demand across our nationwide network.” – Shane Madden, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the company’s cautionary statement.